{
    "clinical_study": {
        "@rank": "56966", 
        "arm_group": [
            {
                "arm_group_label": "Arm I (omega-3 fatty acid)", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive omega-3 fatty acid PO QD or BID for 12 weeks. Patients complete quality-of-life assessment form."
            }, 
            {
                "arm_group_label": "Arm II (placebo)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients receive placebo PO QD or BID for 12 weeks. Patients complete quality-of-life assessment form."
            }
        ], 
        "brief_summary": {
            "textblock": "This randomized pilot clinical trial studies omega-3 fatty acid in treating pain in patients\n      with breast or ovarian cancer receiving paclitaxel. Omega-3 fatty acid may help lessen pain\n      caused by paclitaxel in patients with breast or ovarian cancer."
        }, 
        "brief_title": "Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel", 
        "completion_date": {
            "#text": "August 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Breast Cancer", 
            "Ovarian Neoplasm", 
            "Pain"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Neoplasms", 
                "Ovarian Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To determine whether omega-3 fatty acids can prevent or ameliorate paclitaxel associated\n      pain syndrome (P-APS) in cancer patients.\n\n      SECONDARY OBJECTIVES:\n\n      I. To determine whether omega-3 fatty acids can prevent development of peripheral\n      neuropathy.\n\n      II. To assess tolerability of omega -3 fatty acids in this setting. III. To compare quality\n      of life (QOL) with omega 3 fatty acids supplementation versus placebo.\n\n      OUTLINE: Patients are randomized to 1 of 2 treatment arms.\n\n      ARM I: Patients receive omega-3 fatty acid orally (PO) once daily (QD) or twice daily (BID)\n      for 12 weeks.\n\n      ARM II: Patients receive placebo PO QD or BID for 12 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients have a diagnosis of breast cancer or ovarian cancer\n\n          -  Patients are scheduled to receive weekly paclitaxel at 70-90 mg/m^2 for a minimum of\n             2 months; 3 out of 4 weeks is allowed\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2\n\n          -  Patients must not have taken omega-3-fatty acid supplements within the past 1 month\n             prior to registration and must agree to refrain from use of omega- 3 fatty acid\n             supplements from sources outside the study\n\n          -  Patients must not be on nonsteroidal anti-inflammatory drugs (NSAIDS) or aspirin for\n             at least 1 week prior to registration; NSAIDS or aspirin are allowed after enrollment\n\n          -  Patients must not have received any other analgesics (opiates and tramadol) 1 week\n             prior to registration; analgesics (opiates and tramadol) are allowed after enrollment\n\n          -  Patients must have the ability to complete questionnaires by themselves or with\n             assistance\n\n          -  Patients must not be on anticoagulation medication (heparin/ warfarin) within 28 days\n             prior to registration, because of increased risk of bleeding\n\n          -  Concurrent treatment with carboplatin +/- bevacizumab is allowed\n\n          -  Concurrent treatment with human epidermal growth factor receptor (Her2 neu) targeted\n             therapy is allowed\n\n        Exclusion Criteria:\n\n          -  Known allergy to omega 3 fatty acids, fish or shellfish\n\n          -  Pre-existing diagnosis of peripheral neuropathy\n\n          -  Diagnosis of fibromyalgia\n\n          -  Concurrent planned neutrophil colony stimulating factor therapy\n\n          -  Prior exposure to paclitaxel within the last 6 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01821833", 
            "org_study_id": "INST 1211", 
            "secondary_id": "NCI-2013-00443"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm I (omega-3 fatty acid)", 
                "description": "Given PO", 
                "intervention_name": "omega-3 fatty acid", 
                "intervention_type": "Dietary Supplement", 
                "other_name": [
                    "fish oil", 
                    "n-3 fatty acid", 
                    "O3FA"
                ]
            }, 
            {
                "arm_group_label": "Arm II (placebo)", 
                "description": "Given PO", 
                "intervention_name": "placebo", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "PLCB"
            }, 
            {
                "arm_group_label": [
                    "Arm I (omega-3 fatty acid)", 
                    "Arm II (placebo)"
                ], 
                "description": "Ancillary studies", 
                "intervention_name": "quality-of-life assessment", 
                "intervention_type": "Other", 
                "other_name": "Quality of life assessment"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Paclitaxel"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "omega-3", 
            "fatty acids", 
            "paclitaxel", 
            "acute pain syndrome", 
            "peripheral neuropathy", 
            "chemotherapy induced neuropathy"
        ], 
        "lastchanged_date": "December 5, 2013", 
        "link": [
            {
                "description": "University of New Mexico Cancer Center", 
                "url": "http://cancer.unm.edu"
            }, 
            {
                "description": "New Mexico Cancer Care Alliance", 
                "url": "http://www.nmcca.org"
            }
        ], 
        "location": [
            {
                "contact": {
                    "email": "zdayao@salud.unm.edu", 
                    "last_name": "Zoneddy R. Dayao, MD", 
                    "phone": "505-925-5490"
                }, 
                "facility": {
                    "address": {
                        "city": "Albuquerque", 
                        "country": "United States", 
                        "state": "New Mexico", 
                        "zip": "87106"
                    }, 
                    "name": "University of New Mexico Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Zoneddy R. Dayao", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Wendy Burman, RN", 
                    "phone": "505-559-6113"
                }, 
                "facility": {
                    "address": {
                        "city": "Albuquerque", 
                        "country": "United States", 
                        "state": "New Mexico", 
                        "zip": "87110"
                    }, 
                    "name": "Presbyterian Medical Group"
                }, 
                "investigator": {
                    "last_name": "Bernard Agbemadzo, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Pilot Randomized, Placebo Controlled, Double Blind Study of Omega-3 Fatty Acids to Prevent Paclitaxel Associated Acute Pain Syndrome", 
        "overall_contact": {
            "email": "vparks@salud.unm.edu", 
            "last_name": "Valerie Parks, RN", 
            "phone": "505-925-0390"
        }, 
        "overall_official": {
            "affiliation": "University of New Mexico Cancer Center", 
            "last_name": "Zoneddy Dayao", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Differences between groups will analyzed via t-tests or Wilcoxon rank-sum tests as appropriate.", 
            "measure": "Mean severity of pain", 
            "safety_issue": "No", 
            "time_frame": "Up to 1 month after completion of therapy"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01821833"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Fisher's exact test will be used for the incidence variable with 95% confidence intervals.", 
            "measure": "Incidence of pain or relief", 
            "safety_issue": "No", 
            "time_frame": "Up to 1 month after completion of therapy"
        }, 
        "source": "New Mexico Cancer Care Alliance", 
        "sponsors": {
            "collaborator": {
                "agency": "Alliance Healthcare Foundation", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "New Mexico Cancer Care Alliance", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}